Navigation Links
Epilepsy researcher at the Children's Hospital of Philadelphia receives scientific prize
Date:12/13/2010

Douglas A. Coulter, Ph.D., a neuroscientist at The Children's Hospital of Philadelphia, received the 2010 Epilepsy Research Recognition Award for Basic Science from the American Epilepsy Society. The Society honored Dr. Coulter's pioneering contributions to epilepsy research on Monday, Dec. 6 at its Annual Meeting in San Antonio.

Considered the most prestigious prizes for research in epilepsy, the Epilepsy Research Recognition Awards annually honor active scientists for professional excellence and distinguished research. One award recognizes a basic science investigator, the other a clinical investigator.

The Basic Science Award to Dr. Coulter acknowledges his "highly original and pioneering contributions to the understanding of altered brain cell and circuit function in the development of epilepsy." He has studied a fundamental research questionhow does an injury to neurons ultimately result in the recurrent seizures that characterize epilepsy?

Dr. Coulter has used a variety of approachesphysiological, anatomical and molecularto study the development of epilepsy, both in animal models and in human brains. One technique he has developed in his laboratory is a high-speed imaging method that captures how molecular changes in individual brain cells influence the function of brain signaling networks.

Some of his most recent research has focused on abnormal changes in brain cells called astrocytes reduce inhibition signals in the brain, allowing uncontrolled firing among neurons to give rise to epileptic seizures.

Epilepsy affects an estimated 50 million people, 3 million of them in the United States. It is the third most common neurological disorder, after Alzheimer's disease and stroke.

Dr. Coulter's research has also included studying cellular activities of several anti-epileptic drugs. Coulter said, "The ultimate goal of our research is to help translate detailed knowledge of how epilepsy develops into better therapies for treating children and adults with epilepsy."

Dr. Coulter is an investigator at The Children's Hospital of Philadelphia Research Institute. He also is a professor of Pediatrics and Neuroscience at the University of Pennsylvania School of Medicine, where he directs the University's Center for Dynamic Imaging of Neuronal Function. He has received a Javits Neuroscience Investigator Award of the National Institute of Neurological Disorders and Stroke (NINDS), and was Chair of the second Gordon Research Conference on Epilepsy.

He is active in many educational and scientific activities of the American Epilepsy Society, and has served as an editor of the journals Epilepsy Currents, Epilepsy Research, and Epilepsia, among other publications. He is also a standing member of an NINDS study section.


'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert  

Related biology news :

1. Rare genetic disorder gives clues to autism, epilepsy, mental retardation
2. Drops in blood oxygen levels may be key to sudden death in some epilepsy patients
3. International team discovers gene associated with epilepsy
4. Epilepsy drug shows potential for Alzheimers treatment
5. Rice University study finds possible clues to epilepsy, autism
6. Researchers discover that gene switches on during development of epilepsy
7. Drug prevents seizure progression in model of epilepsy
8. Rutgers research tackles childhood epilepsy
9. More than fish bait: Worms unlock secrets to new epilepsy treatments
10. Twins provide clue that genetic epilepsy can originate in the embryo
11. Genetic defect found to cause severe epilepsy and mental retardation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Epilepsy researcher at the Children's Hospital of Philadelphia receives scientific prize
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: